BioReliance: Merck to invest 100 million to build new viral vector and gene therapy manufacturing facility in US
Merck, a leading science and technology company, announced a second Carlsbad, California, US─based facility for its BioReliance viral and gene therapy service offering.
Read full article »
President & CEO
Charles C. Harwood, Jr
BioReliance provides nonclinical testing and manufacturing services for pharmaceutical and biotechnology industries.
Read more